John J. Miller, MD

Learn more about how to best assess and treat tardive dyskinesia.

Phillip R. Muskin, MD, discusses the complexities of prescribing antipsychotics, emphasizing patient collaboration and the importance of evaluating treatment strategies.

Take a look at innovative GSK-3β inhibitors to enhance efficacy and reduce adverse effects seen in lithium with Jonathan M. Meyer, MD, DLFAPA, at the 2025 APA Annual Meeting.

Discover how insulin influences mood and cognition, revealing new therapeutic possibilities for depression and bipolar disorder, in this discussion with Roger McIntyre, MD, FRCPC, at the 2025 APA Annual Meeting.

Experts discuss groundbreaking insights on ketamine's role in treating depression, highlighting its rapid effects and potential to transform psychopharmacology.

How does adult ADHD differ from pediatric ADHD? Jeffrey Newcorn, MD, shared his expertise at the 2025 APA Annual Meeting.

Antipsychotic plasma levels play a critical role of in treatment decisions. Learn more in this conversation from the 2025 APA Annual Meeting.

John J. Miller, MD, discusses the updates to the delirium practice guidelines with Mark A. Oldham, MD

The therapeutic alliance in psychiatry: enhancing patient engagement and treatment outcomes through effective communication and collaboration.

For much of our 155-year history, the United States has been the global leader in research, including in its provision of funding for education and training in science, to the great advantage of itself and the wider world.

Psychiatric Times Editor in Chief John J. Miller, MD, shares thoughts on psychiatry's response to the recent executive order.

Epidemiological data show that rates of anxiety, depression, self-injurious behaviors, and suicidality increased for Gen Z in significantly higher numbers than previous generations.

At the beginning of this year, US Surgeon General Vivek H. Murthy, MD, MBA, issued a health advisory warning about the link between alcohol use and the risk of cancer. Learn more about its implications for psychiatry here.

COVID-19 increased the usage of telemedicine drastically, but is that always a good thing?

Come celebrate the evolution of Psychiatric Times and psychiatry as a whole!

Check out these examples of neuroplasticity.

How can we optimize and expand our knowledge of neuroplasticity?

Check out 2 new psychopharmacology innovations!

Psychiatry: one of the most dynamic and rapidly evolving specialties in medicine.

Are you attending Real Psychiatry in January?

The medication treatment of schizophrenia has finally diversified to a novel neurotransmitter system: the muscarinic cholinergic system.

There is still no formal or professional recognition of complex PTSD as a very different disorder than what DSM-5-TR describes for PTSD.

John J. Miller, MD, discusses the risks of untreated PTSD and the importance of implementing more therapeutic tools into treatment paradigms.

Addressing the importance of safe treatments for PTSD, Dr John Miller discusses adverse effect management practices and the role of REMS protocols.

Focusing on the future of PTSD treatment, Dr John Miller outlines how novel treatments can address current challenges and unmet needs in the therapeutic landscape.

John J. Miller, MD, provides an overview of the symptom clusters of PTSD and treatments that are being looked at to improve patient care.

The Psychiatric Times editor-in-chief shares perspectives on how a novel treatment, MDMA-assisted therapy, can potentially change the treatment landscape and improve patients’ lives.

John J. Miller, MD, discusses how the diagnosis and treatment of posttraumatic stress disorder (PTSD) has evolved over time.

Psychiatry is such a young field attempting to improve functioning and quality of life for so many diverse and complex brain disorders that it should be no surprise that our treatment outcomes spread across the spectrum from much improved to progressive decline.